We will break the new drug creation system for foreign patent medicines to meet the "bumper harvest"

　　Xinhua News Agency, Beijing, February 22 (Reporter Chen Fang, Hu Zhe) lung cancer, leukemia and other areas to break the monopoly of foreign patent drugs, domestic small molecule targeted anti-cancer drug market to promote foreign patent drugs in China more than 50% price reduction ... ... National Science and Technology Significant special results not only 4G mobile communications, Beidou satellite navigation these "tall hard technology", more closely related to the health of the people of biomedical technology innovation.

　　Reporters on the 22nd in the Ministry of Science and Technology held a "new drug to create a national science and technology major project" results conference learned that China has broken the monopoly of foreign patent drugs in lung cancer, leukemia, drug resistant bacteria prevention and control, research and innovation capacity of bio pharmaceutical industry and sustainable development of the industry has increased, achieved stage success and fruitful.

　　The new drug to create a special implementation of the Office of the management of the Office of the National Health and Health Education Commission Director Qin Huaijin introduction, as of the "12th Five-Year" at the end of the new drug creation has accumulated a total of 90 varieties of new drug certificates, including hand, foot and mouth disease EV71 vaccine 24 A new type of new drugs, is the implementation of the total implementation of the total of 5 times; technological transformation of more than 200 kinds of clinical urgently needed varieties, involving 15.3% of the national essential drugs, drug quality was significantly improved; domestic small molecule targeting anti-cancer drugs "icotinib hydrochloride "listing, to promote foreign patent drugs in China, more than 50% price reduction; for new outbreaks of infectious diseases, successfully developed Ebola virus vaccine, recombinant peramivir such as emergency medicine, as a major outbreak of joint prevention and control to provide technical support and bio security.

　　In addition, Lamotrigine was approved by the US FDA, and risperidone microspheres were approved by the US FDA and submitted directly to new drug applications. Di-ao-xin-xue-kang and Salvia capsules were approved by the European Union. "China's new drug research and innovation ability has been internationally recognized." Qin Huaijin Said.

　　Drug safety issues related to the lives and health of the people in the world have had a painful lesson, non clinical safety evaluation of drugs is extremely important essential stages of drug development in a drug ring. Special technical chief engineer, academician of Academy of engineering, Sang Guowei created Chinese said that in the new drug creation special support, China's drug non-clinical safety evaluation platform construction has made a series of major breakthroughs, new drug pre-clinical safety assessment work has been with international standards, evaluation platform core key technology reached the international advanced level, strong support for the new drug research and development in China, to ensure the public safety.

　　Previous post:Outstanding achievements of new drug in China

　　Next post:The state department's deployment to accelerate the drug review and generic medicines spring approach

　　TypeInfo: Company News

　　Keywords for the information: